NKMAX, Four Research Abstracts Accepted at ASCO Conference

[Asia Economy Reporter Jang Hyowon] NKMAX announced on the 28th that a total of four abstracts have been accepted at the American Society of Clinical Oncology (ASCO). Following the American Association for Cancer Research (AACR) held earlier, bio companies selected for the upcoming ASCO conference in June are gaining attention. ASCO is one of the world's top three cancer conferences and is known for presenting late-stage clinical results.

The four abstracts include two submitted by NKMAX's U.S. subsidiary NKGen Biotech, and one each from Affimed NV (NASDAQ: AFMD), which is conducting joint clinical trials, and Vejle Hospital in Denmark. Affimed, a Nasdaq-listed company developing bispecific antibodies, also attracted attention by revealing significant clinical results at the April AACR conference. Vejle Hospital is Denmark's national cancer hospital, known for excellence in breast cancer, lymphoma, and lung cancer treatment.

The four accepted abstracts cover ▲ Phase 1 U.S. clinical trial of SuperNK (SNK01) monotherapy in refractory solid tumors, ▲ SuperNK combined with Bavencio (generic name: Avelumab), ▲ Phase 1/2a U.S. clinical trial in EGFR-positive solid tumors, and ▲ a study measuring treatment response rates in lung cancer patients using the NK Vue kit. It is noted that having four abstracts from a domestic bio company accepted at ASCO is an unusual achievement.

Particularly, additional data on the Phase 1 clinical trial for refractory solid tumors to be presented at ASCO is highly anticipated. Previously, NKMAX reported an interim result of complete remission (CR) in a patient with advanced sarcoma in August last year, and recently disclosed CR results in a sarcoma patient who received compassionate use approval.

Kim Taehee, a researcher at KB Securities, emphasized, “It is very positive that four abstracts were accepted at ASCO, which mainly presents late-stage clinical results. NK cell therapy is a technology gaining attention recently, and among domestic companies, NKMAX is leading.”

This content was produced with the assistance of AI translation services.